Bristol-Myers Squibb Co. (BMY)

49.86
NYSE : Health Technology
Prev Close 49.96
Day Low/High 49.63 / 50.11
52 Wk Low/High 44.30 / 67.44
Avg Volume 18.30M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 81.56B
EPS 3.00
P/E Ratio 16.60
Div & Yield 1.64 (3.23%)
AUGUSTUS Demonstrates Favorable Safety Results Of Eliquis® Versus Vitamin K Antagonists In Non-Valvular Atrial Fibrillation Patients With Acute Coronary Syndrome And/or Undergoing Percutaneous Coronary Intervention

AUGUSTUS Demonstrates Favorable Safety Results Of Eliquis® Versus Vitamin K Antagonists In Non-Valvular Atrial Fibrillation Patients With Acute Coronary Syndrome And/or Undergoing Percutaneous Coronary Intervention

The Bristol-Myers Squibb- Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) and recent acute coronary...

Nvidia's Head-Turning Deal for Mellanox Technologies: 7 Takeaways

Nvidia's Head-Turning Deal for Mellanox Technologies: 7 Takeaways

Nvidia and Mellanox have many common customers, and also a major common competitor in Intel.

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty one cents ($0.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

Bristol-Myers Squibb To Announce Results For First Quarter 2019 On April 25, 2019

Bristol-Myers Squibb To Announce Results For First Quarter 2019 On April 25, 2019

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2019 on Thursday, April 25, 2019.

Fear of Big Sellers: Cramer's 'Mad Money' Recap (Wed. 3/6/19)

Fear of Big Sellers: Cramer's 'Mad Money' Recap (Wed. 3/6/19)

Jim Cramer says investors need to consider the bear the motivation, and they need to consider the big sellers they'll have to outrun.

Bristol-Myers Squibb To Take Part In The Barclays 2019 Global Healthcare Conference

Bristol-Myers Squibb To Take Part In The Barclays 2019 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in a fireside chat at the Barclays 2019 Global Healthcare Conference on Wednesday, March 13, 2019, in Miami.

Starboard Mails Letter With Important Message To All Bristol-Myers Squibb Stockholders

Starboard Mails Letter With Important Message To All Bristol-Myers Squibb Stockholders

Reiterates Belief that the Proposed Merger with Celgene is Ill-Advised and Not in the Best Interests of Bristol-Myers Stockholders

Bristol-Myers Squibb Files Investor Presentation And Board Of Directors Sends Letter To Shareholders Regarding Pending Transaction With Celgene

Bristol-Myers Squibb Files Investor Presentation And Board Of Directors Sends Letter To Shareholders Regarding Pending Transaction With Celgene

Bristol-Myers Squibb Company (NYSE:BMY) today filed an investor presentation with the Securities and Exchange Commission (SEC), and the Board of Directors sent an open letter to the Company's shareholders regarding the previously announced definitive...

Bristol-Myers Squibb To Take Part In The Cowen And Company 39th Annual Health Care Conference

Bristol-Myers Squibb To Take Part In The Cowen And Company 39th Annual Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in a fireside chat at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, in Boston.

Let’s Explore the Reasons I Remain Sidelined

FAANG rallies are fine when breadth is playing along. FAANG rallies that suck the life out of other stocks (breadth) to feed themselves are bearish.

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

Bristol-Myers Squibb Issues Statement In Response To Starboard's Letter

Bristol-Myers Squibb Issues Statement In Response To Starboard's Letter

Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement in response to a letter from Starboard Value ("Starboard"): Bristol-Myers Squibb welcomes the opinions of all of its stockholders and will review Starboard's letter and respond...

Celgene Shares Slide as Key Bristol-Myers Investor Queries $74 Billion Takeover

Celgene Shares Slide as Key Bristol-Myers Investor Queries $74 Billion Takeover

Celgene shares traded sharply lower Thursday after one of Bristol-Myers Squibb's key investors said it $74 billion takeover bid for the cancer drug specialist was too risky and expensive.

Starboard Delivers Open Letter To Bristol-Myers Squibb Stockholders

Starboard Delivers Open Letter To Bristol-Myers Squibb Stockholders

Believes the Proposed Merger with Celgene is Ill-Advised and Not in the Best Interests of Bristol-Myers Stockholders

Bristol-Myers Squibb Announces Filing Of Definitive Proxy Statement In Connection With Proposed Merger With Celgene

Bristol-Myers Squibb Announces Filing Of Definitive Proxy Statement In Connection With Proposed Merger With Celgene

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has filed definitive proxy materials with the U.

Bristol-Myers Squibb Provides Update On Pending Transaction With Celgene

Bristol-Myers Squibb Provides Update On Pending Transaction With Celgene

Bristol-Myers Squibb Company (NYSE:BMY) today provided an update on its proposed acquisition of Celgene Corporation (NASDAQ:CELG).

Merck Shares Drop After Keytruda Treatment Fails Late-Stage Liver Cancer Trial

Merck Shares Drop After Keytruda Treatment Fails Late-Stage Liver Cancer Trial

Merck shares slipped lower in pre-market trading Wednesday after the drugmaker said one of its key liver cancer treatments failed a late-stage trial only months after getting accelerated approval from the U.S. Food & Drug Administration.

Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response In Pre-Treated Patients With Metastatic Castration-Resistant Prostate Cancer

Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response In Pre-Treated Patients With Metastatic Castration-Resistant Prostate Cancer

Bristol-Myers Squibb Company (NYSE: BMY) today announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit At 30-Month Follow-up In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit At 30-Month Follow-up In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced new results from the Phase 3 CheckMate -214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients...

European Commission Approves Bristol-Myers Squibb's Sprycel (dasatinib) In Combination With Chemotherapy For Treatment Of Pediatric Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

European Commission Approves Bristol-Myers Squibb's Sprycel (dasatinib) In Combination With Chemotherapy For Treatment Of Pediatric Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive...

Bristol-Myers Squibb To Take Part In Guggenheim Healthcare Talks Idea Forum

Bristol-Myers Squibb To Take Part In Guggenheim Healthcare Talks Idea Forum

Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019, in New York.

When Everyone Sees the Obvious the Obvious Rarely Happens

Right now it feels as though everyone sees the obvious resistance and overbought situation.

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.

Stocks Rise Ahead of Alphabet Earnings

Stocks Rise Ahead of Alphabet Earnings

Stocks rose Monday amid another rush of earnings reports this week including Alphabet results due after the bell.

Report Says Starboard Value Takes Stake in Bristol-Myers

Report Says Starboard Value Takes Stake in Bristol-Myers

Hedge fund Starboard Value took a stake in the company last month, a Bloomberg report says.

Jim Cramer on Starboard's Stake in Bristol-Myers Squibb and Papa Johns

Jim Cramer on Starboard's Stake in Bristol-Myers Squibb and Papa Johns

Jim Cramer reacts to Starboard's stake in Bristol-Myers Squibb and Papa Johns.

Jim Cramer's Thoughts on Google, Starboard's Investments, and Tesla

Jim Cramer's Thoughts on Google, Starboard's Investments, and Tesla

Here's what Jim Cramer thinks about Google's earnings, Starboard's investments and Tesla's acquisition.

Jim Cramer: Tesla, Starboard and Google Earnings

Jim Cramer: Tesla, Starboard and Google Earnings

Jim Cramer weighs in on Starboard's investments, Tesla's purchase and Alphabet's earnings.

TheStreet Quant Rating: C+ (Hold)